297 related articles for article (PubMed ID: 34681959)
41. Redox-Responsive Phase-Separating Peptide as a Universal Delivery Vehicle for CRISPR/Cas9 Genome Editing Machinery.
Sun Y; Xu X; Chen L; Chew WL; Ping Y; Miserez A
ACS Nano; 2023 Sep; 17(17):16597-16606. PubMed ID: 37584415
[TBL] [Abstract][Full Text] [Related]
42. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
[TBL] [Abstract][Full Text] [Related]
43. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
[TBL] [Abstract][Full Text] [Related]
44. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide.
Wang HX; Song Z; Lao YH; Xu X; Gong J; Cheng D; Chakraborty S; Park JS; Li M; Huang D; Yin L; Cheng J; Leong KW
Proc Natl Acad Sci U S A; 2018 May; 115(19):4903-4908. PubMed ID: 29686087
[TBL] [Abstract][Full Text] [Related]
45. A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells.
Geng BC; Choi KH; Wang SZ; Chen P; Pan XD; Dong NG; Ko JK; Zhu H
Acta Pharmacol Sin; 2020 Nov; 41(11):1427-1432. PubMed ID: 32555510
[TBL] [Abstract][Full Text] [Related]
46. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
[TBL] [Abstract][Full Text] [Related]
47. Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles.
Ma T; Chen X; Wang M
Chembiochem; 2023 May; 24(9):e202200801. PubMed ID: 36780174
[TBL] [Abstract][Full Text] [Related]
48. Virus-Induced Gene Editing and Its Applications in Plants.
Zhang C; Liu S; Li X; Zhang R; Li J
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142116
[TBL] [Abstract][Full Text] [Related]
49. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
50. Synthetic nanoparticles for the delivery of CRISPR/Cas9 gene editing system: classification and biomedical applications.
Zheng Q; Wang W; Zhou Y; Mo J; Chang X; Zha Z; Zha L
Biomater Sci; 2023 Aug; 11(16):5361-5389. PubMed ID: 37381725
[TBL] [Abstract][Full Text] [Related]
51. Recent trends in CRISPR-Cas system: genome, epigenome, and transcriptome editing and CRISPR delivery systems.
Bae T; Hur JW; Kim D; Hur JK
Genes Genomics; 2019 Aug; 41(8):871-877. PubMed ID: 31119685
[TBL] [Abstract][Full Text] [Related]
52. Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies.
Singh D
AAPS PharmSciTech; 2024 Jun; 25(5):129. PubMed ID: 38844700
[TBL] [Abstract][Full Text] [Related]
53. CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy.
Wang D; Chen L; Li C; Long Q; Yang Q; Huang A; Tang H
J Nanobiotechnology; 2022 Jan; 20(1):27. PubMed ID: 34991617
[TBL] [Abstract][Full Text] [Related]
54. Pre-clinical non-viral vectors exploited for
Rouatbi N; McGlynn T; Al-Jamal KT
Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
[TBL] [Abstract][Full Text] [Related]
55. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
[TBL] [Abstract][Full Text] [Related]
56. Integrating Combinatorial Lipid Nanoparticle and Chemically Modified Protein for Intracellular Delivery and Genome Editing.
Chang J; Chen X; Glass Z; Gao F; Mao L; Wang M; Xu Q
Acc Chem Res; 2019 Mar; 52(3):665-675. PubMed ID: 30586281
[TBL] [Abstract][Full Text] [Related]
57. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
[TBL] [Abstract][Full Text] [Related]
58. Non-viral delivery of genome-editing nucleases for gene therapy.
Wang M; Glass ZA; Xu Q
Gene Ther; 2017 Mar; 24(3):144-150. PubMed ID: 27797355
[TBL] [Abstract][Full Text] [Related]
59. Packaging and Uncoating of CRISPR/Cas Ribonucleoproteins for Efficient Gene Editing with Viral and Non-Viral Extracellular Nanoparticles.
Mazurov D; Ramadan L; Kruglova N
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992399
[TBL] [Abstract][Full Text] [Related]
60. Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing.
Aquino-Jarquin G
Mol Genet Metab; 2021; 134(1-2):77-86. PubMed ID: 34391646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]